Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP

The inhibitor of apoptosis protein, XIAP, is frequently overexpressed in chemoresistant human tumours. An antisense oligonucleotide (AEG 35156/GEM 640) that targets XIAP has recently entered phase I trials in the UK. Method validation data are presented on three pharmacodynamic assays that will be u...

Descripción completa

Detalles Bibliográficos
Autores principales: Cummings, J, Ward, T H, LaCasse, E, Lefebvre, C, St-Jean, M, Durkin, J, Ranson, M, Dive, C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362094/
https://www.ncbi.nlm.nih.gov/pubmed/15685240
http://dx.doi.org/10.1038/sj.bjc.6602363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362094/
https://www.ncbi.nlm.nih.gov/pubmed/15685240
http://dx.doi.org/10.1038/sj.bjc.6602363

Ejemplares similares